MyFinsight
Home
Blog
About
Contact
Download
Download image
Net income
$2,021M
Amortization expense
$596M
(-0.50%↓ Y/Y)
Proceeds from sales of
marketable debt securities
$2,520M
Stock-based compensation
expense
$218M
(4.31%↑ Y/Y)
Other, net
-$183M
(-101.10%↓ Y/Y)
Deferred income taxes
$179M
(189.95%↑ Y/Y)
Accounts receivable, net
-$134M
(-69.62%↓ Y/Y)
Acquired in-process
research and development...
$107M
(-57.71%↓ Y/Y)
Depreciation expense
$93M
(-4.12%↓ Y/Y)
Prepaid expenses and
other
-$5M
(58.33%↑ Y/Y)
Proceeds from maturities
of marketable debt...
$36M
Net cash provided by
operating activities
$2,544M
(44.79%↑ Y/Y)
Net cash provided by
(used in) investing...
$1,770M
(526.51%↑ Y/Y)
Canceled cashflow
$992M
Canceled cashflow
$787M
Net change in cash
and cash...
$65M
(103.15%↑ Y/Y)
Canceled cashflow
$4,250M
Accrued and other
liabilities
-$702M
(-187.70%↓ Y/Y)
Net (gain) loss from
equity securities
$142M
(133.33%↑ Y/Y)
Accounts payable
-$67M
(36.19%↑ Y/Y)
Inventories
$52M
(-76.68%↓ Y/Y)
Income tax assets and
liabilities, net
-$29M
(94.75%↑ Y/Y)
Proceeds from issuances
of common stock
$166M
(-34.13%↓ Y/Y)
Purchases of marketable
debt securities
$525M
Purchases of property,
plant and equipment
$117M
(12.50%↑ Y/Y)
Acquisitions, including
in-process research and...
$109M
(-60.07%↓ Y/Y)
Purchases of equity
securities
$19M
(18.75%↑ Y/Y)
Other investing
activities, net
$17M
(-26.09%↓ Y/Y)
Net cash used in
financing activities
-$4,239M
(-23.73%↓ Y/Y)
Effect of exchange rate
changes on cash and cash...
-$11M
(-157.89%↓ Y/Y)
Canceled cashflow
$166M
Repayments of debt and other
obligations
$2,766M
(56.98%↑ Y/Y)
Payments of dividends
$1,040M
(2.97%↑ Y/Y)
Repurchases of common stock
under repurchase...
$419M
(-42.60%↓ Y/Y)
Other financing
activities, net
-$179M
(-1.70%↓ Y/Y)
Back
Back
Cash Flow
Gilead_Sciences_Logo-svg
GILEAD SCIENCES, INC. (GILD)
Gilead_Sciences_Logo-svg
GILEAD SCIENCES, INC. (GILD)
source: myfinsight.com